Days before Endo International filed for Chapter 11 protection, the pharmaceutical company, which is mired in opioid epidemic-related litigation, quietly doled out “excessive and inappropriate” bonuses to the firm’s executives, including its top lawyer. 

That’s according to a recent filing with the U.S. Bankruptcy Court for the Southern District of New York, where a committee of seven attorneys general and a bankruptcy trustee argued that Endo has attempted to “escape accountability and enrich its executives” through millions in “secret” bonuses.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]